Celularity (CELU) news
Recent news
Cellularity provides update regarding Nasdaq listing compliance
Celularity Inc. (Nasdaq: CELU) has regained compliance with Nasdaq Listing Rule 5250(c)(1) following the timely filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The company submitted the report on April 30, 2026, and received confirmation from Nasdaq on May 1,…
AInvest Wire · 5d agoSanuwave Health - market disruption impacting Ultramist system sales
Celularity, Inc. has completed the sale of its UltraMIST® Ultrasound Healing Therapy asset to Sanuwave Health, Inc. [OTC PINK: SNWV], granting Sanuwave partnership rights to Celularity’s wound care biologic product portfolio. This transaction aligns with Celularity’s strategic focus on surgical…
AInvest Wire · Jun 16, 2026ImportantCelularity files to sell 6.52 million shares of Class A common stock for holders
Celularity files to sell 6.52 million shares of Class A common stock for holders Celularity, Inc. (Nasdaq: CELU), a leading biotechnology company specializing in placental-derived allogeneic cell therapies and biomaterial products, recently announced a registered direct offering of 8,571,428 shares…
AInvest Wire · Jan 30, 2025Celularity jumps 16% premarket after insider bought $5.33M shares
AInvest Wire · Jan 18, 2024Celularity confirms commercialization pact with Biocellgraft.
AInvest Wire · Jan 4, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.